Novartis case in India
From PHM Oz
(Difference between revisions)
DavidLegge (Talk | contribs) |
|||
| Line 1: | Line 1: | ||
| − | + | Background to the early development of IP in India and process-only patenting | |
| − | + | ||
| − | Background to the early development of IP in India | + | |
Early pressure to change (marketing approval). | Early pressure to change (marketing approval). | ||
| − | Accession to WTO and TRIPS | + | Accession to WTO and TRIPS from 2005 and requirement to introduce product patenting as well as process patenting. |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | The Novartis case. See documentation at Berne Declaration [[http://www.evb.ch/en/p25012749.html]] | |
[[Intellectual Property and Pharmaceuticals|Back to IP home]] | [[Intellectual Property and Pharmaceuticals|Back to IP home]] | ||
Revision as of 05:11, 9 July 2007
Background to the early development of IP in India and process-only patenting
Early pressure to change (marketing approval).
Accession to WTO and TRIPS from 2005 and requirement to introduce product patenting as well as process patenting.
The Novartis case. See documentation at Berne Declaration [[1]]
